Global /China /Healthcare /Drug Manufacturers - General /688091

Shanghai Yizhong Pharmaceutical Co., Ltd.

688091

• SSE: 688091 • Delayed

55.35CNY 0.7%

8.18 USD

As of 16 June 2026, Shanghai Yizhong Pharmaceutical Co., Ltd. has a market cap of $1.67B USD, ranking #7921 globally and #2007 in China. It ranks #664 in the Healthcare sector, and #254 in the Drug Manufacturers - General industry.

Global Rank

7921

Country Rank

2007

Sector Rank

664

Industry Rank

254

Key Stats

Market Cap

$1.67BUSD

11.29B CNY

Enterprise Value

$1.61BUSD

10.9B CNY

Revenue (TTM)

$48.03MUSD

325.2M CNY

Net Income (TTM)

$10.06MUSD

68.11M CNY

Profit Margin

21%

PE Ratio

166.7

PS Ratio

34.7

PB Ratio

7.8

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jingsong Zhou open_in_new

Employees

415

Founded

2009

Website

yizhongpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.7%	1.6%	-4.3%	0.5%	-0.8%	17%	30%	-11%	62%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688091 上海谊众药业股份有限公司 Class A ISIN: CNE1000050F4 Shares Out.: Shares Outstanding: 204.799M¹ Shares Float: 99.813M² TV: TradingView: SSE: 688091 SA: Stock Analysis: SHA: 688091 YF: Yahoo Finance: 688091.SS GF: Google Finance: SHA: 688091 BA: Barron's: 688091 MS: Morningstar: XSHG: 688091	55.35 CNY	TV: TradingView: SSE: 688091 SA: Stock Analysis: SHA: 688091 YF: Yahoo Finance: 688091.SS GF: Google Finance: SHA: 688091 BA: Barron's: 688091 MS: Morningstar: XSHG: 688091

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.89B 364.89B CNY 3K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.67B 336.36B CNY 3K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.52B 111.89B CNY 891%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 861%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 46K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 33K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 22K%	97.4	United States
Roche Holding AG SIX: RO	$320.51B 256.25B CHF 19K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.14B 215.59B GBP 17K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 16K%	15.1	United States

chevron_leftBack